Patient satisfaction following midurethral sling surgeries

Maldonado, P.A.; Kogutt, Benjamin K.; Wai, Clifford Y.

doi:10.1097/gco.0000000000000097

Cited by 6 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly to other authors [12,22,28,42,45,[52][53][54][55][56][57], a subjective cure and improvement was noted in over 80% of women in both groups. Based on an analysis of VAS and IIQ-7, there were no significant differences in quality of life between the groups at the 6-month follow-up.…”

Section: Discussionsupporting

confidence: 82%

Intraoperative and early postoperative complications in women with stress urinary incontinence treated with suburethral slings: a randomised trial.

Szymański

Zaręba

Jakiel

et al. 2019

Videosurgery and Other Miniinvasive Techniques

View full text Add to dashboard Cite

Introduction: The midurethral sling has become the current standard for the treatment of female stress urinary incontinence. Aim: To assess intraoperative complications, early post-operative complications as well as the efficacy of tension-free vaginal tape: retropubic and trans-obturator tape procedures. Material and methods: The analysis involved 91 tension-free vaginal tape (TVT) and 60 transobturator tape (TOT) procedures. Both groups were comparable in terms of patient characteristics, urodynamic results, and preoperative quality of life (QoL) assessment. The complications were registered, and the effectiveness of the procedures was assessed subjectively by the patients at 1-, 3-, 6-and 12-month follow-up. Results: A significantly lower risk of intraoperative and early post-operative complications was noted in the case of TOT procedures (OR = 0.35%, 95% CI: 0.13-0.92). Moreover, regardless of the method used, patients with two or more vaginal deliveries in their history had a reduced risk of complications, as compared to nulliparas and uniparas (OR = 0.38%, 95% CI: 0.16-0.91). Previous gynaecological surgery and old age increase the risk of complications with borderline significance (OR = 2.5, 95% CI: 0.97-6.3; OR = 2.3, 95% CI: 0.95-5.5 respectively). The rates of cure, improvement and failure were similar in both groups, as was the significant positive change in post-operative life quality. Conclusions: TVT and TOT procedures are characterised by a high cure rate and improvement in the post-operative quality of life. However, it seems that the transobturator approach should be the preferred method of treatment of SUI due to the reduced risk of complications, shorter procedure time, and lower intraoperative blood loss.

show abstract

Section: Discussionsupporting

confidence: 82%

Intraoperative and early postoperative complications in women with stress urinary incontinence treated with suburethral slings: a randomised trial.

Szymański

Zaręba

Jakiel

et al. 2019

Videosurgery and Other Miniinvasive Techniques

View full text Add to dashboard Cite

show abstract

“…Age is a well-known predictor for reduced treatment response for both onabotulinumtoxinA and MUS. [35][36][37] Although evidence suggests that the severity of UUI can affect outcomes of both treatments, 35,38,39 definitions of UI severity in an MUI population are complex, and there are limited data to provide guidance, so participants were not stratified by UI severity.…”

Section: Randomization and Stratificationmentioning

confidence: 99%

Trial Design for Mixed Urinary Incontinence: Midurethral Sling Versus Botulinum Toxin A

Harvie,

Richter,

Sung

et al. 2024

UROGC

View full text Add to dashboard Cite

Importance Mixed urinary incontinence (MUI) is common and can be challenging to manage. Objectives We present the protocol design and rationale of a trial comparing the efficacy of 2 procedures for the treatment of women with MUI refractory to oral treatment. The Midurethral sling versus Botulinum toxin A (MUSA) trial compares the efficacy of intradetrusor injection of 100 U of onabotulinimtoxinA (an office-based procedure directed at the urgency component) versus midurethral sling (MUS) placement (a surgical procedure directed at the stress component). Study Design The MUSA is a multicenter, randomized trial of women with MUI electing to undergo procedural treatment for MUI at 7 clinical centers in the NICHD Pelvic Floor Disorders Network. Participants are randomized to either onabotulinumtoxinA 100 U or MUS. OnabotulinimtoxinA recipients may receive an additional injection between 3 and 6 months. Participants may receive additional treatment (including crossover to the alternative study intervention) between 6 and 12 months. The primary outcome is change from baseline in Urogenital Distress Inventory (UDI) at 6 months. Secondary outcomes include change in UDI at 3 and 12 months, irritative and stress subscores of the UDI, urinary incontinence episodes, predictors of poor treatment response, quality of life and global impression outcomes, adverse events, use of additional treatments, and cost effectiveness. Results Recruitment and randomization of 150 participants is complete and participants are currently in the follow-up phase. Conclusions This trial will provide information to guide care for women with MUI refractory to oral treatment who seek surgical treatment with either onabotulinumtoxinA or MUS.

show abstract

Patient and surgeon goal achievement 10 years following surgery for pelvic organ prolapse and urinary incontinence

et al. 2015

View full text Add to dashboard Cite

show abstract

Patient satisfaction following midurethral sling surgeries

Cited by 6 publications

References 25 publications

Intraoperative and early postoperative complications in women with stress urinary incontinence treated with suburethral slings: a randomised trial.

Intraoperative and early postoperative complications in women with stress urinary incontinence treated with suburethral slings: a randomised trial.

Trial Design for Mixed Urinary Incontinence: Midurethral Sling Versus Botulinum Toxin A

Patient and surgeon goal achievement 10 years following surgery for pelvic organ prolapse and urinary incontinence

Contact Info

Product

Resources

About